Comparing Fulvestrant vs Ibrance
| Fulvestrant | Ibrance (palbociclib) |
|
|---|
| Fulvestrant | Ibrance (palbociclib) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer. Fulvestrant may also be used for purposes not listed in this medication guide. |
Prescription only
Ibrance is a CDK4/6 inhibitor that may be used to treat advanced or metastatic hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer in combination... View more |
Related suggestions Breast Cancer
Popular comparisons
|
|||||||
| More about Fulvestrant | More about Ibrance (palbociclib) | ||||||||
| Ratings & Reviews | |||||||||
|
Fulvestrant has an average rating of 6.5 out of 10 from a total of 53 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 23% reported a negative effect. |
Ibrance has an average rating of 6.8 out of 10 from a total of 85 ratings on Drugs.com. 61% of reviewers reported a positive effect, while 29% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
View all Fulvestrant side effects |
View all Ibrance side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Ibrance prices |
||||||||
| Dosage Forms | |||||||||
|
N/A |
|
||||||||
| Brand Names | |||||||||
| Faslodex |
N/A |
||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
960 hours |
29 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 3 drugs are known to interact with Fulvestrant:
|
A total of 489 drugs are known to interact with Ibrance:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
N/A |
February 03, 2015 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
|||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Arimidex
Arimidex is used to treat breast cancer in postmenopausal women. Learn about side effects ...
Femara
Femara lowers estrogen levels and is used to treat breast cancer in postmenopausal women. Learn ...
Herceptin
Herceptin is used to treat patients with metastatic breast cancer. Learn about side effects ...
Ibrance
Ibrance is used to treat HR-positive, HER2-negative breast cancer in postmenopausal women or men ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.